ImmuCell Corporation

ICCC Healthcare Biotechnology

ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024. In the quarter to June 2026, revenue grew 11.5%, EPS grew 233.3%, free cash flow grew 54.9% and total debt fell 15.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

10.75 0.19 +1.80%
Market cap
$95.9M
P/E
126×
Fwd P/E
−779×
Dividend yield
—
F-score
7/9
Altman Z
2.80
Beneish M
−3.10
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
2.57% (1.88%) (3.81%) 8.27%

+8 more TTM periods

Piotroski F-Score
7 6 7 7
ROA
1.69% (1.22%) (2.37%) 5.15%
ROIC
7.84% 5.04% 3.19% 4.11%
Return on Tangible Assets
2.09% (1.53%) (3.05%) 6.25%
Average Days of Receivables
34.47 32.85 45.14 33.58
Free Cash Flow per Share
0.47 0.38 0.14 0.08
Free Cash Flow
4.23 3.42 1.26 0.75
Other line items

Show all line items

Columns are period end dates